Safety and Tolerability of GS-1179, a Novel, Oral, Long-Acting HSV Helicase-Primase Inhibitor for Recurrent Genital Herpes: Results From a Phase 1b Study

Conference Reports for NATAP

IDSA
ID Week 2026
October 21-24
Washington, DC


Safety and Tolerability of GS-1179, a Novel, Oral, Long-Acting HSV Helicase-Primase Inhibitor for Recurrent Genital Herpes: Results From a Phase 1b Study

	IDSA 2026 Oct 21-24 Wash DC